GDPD6 mRNA levels were shown to be increased in metastasizing as compared to non-metastasizing endometrial carcinomas, and GDPD6 expression was negatively associated with relapse-free survival in endometrial and ovarian cancers (162). Here, GPCPD1 is linked to endometrial carcinoma.